Drug Development

Felicity Thomas is the former Associate Editorial Director of Pharmaceutical Technology, Pharmaceutical Technology Europe, BioPharm International.

Podcasts

In this episode, Ana Ladino provides expert insight into novel excipients in the current and future drug development landscape.

Drug Solutions Podcast: Novel Excipients in Drug Development

Frédérique Bordes-Picard is vice-president of Business Development, Europe, at Nanoform.

Articles

Patient centricity is driving change in drug discovery and development, leading to a a new dawn in therapeutics.

Small is a Powerful Ingredient for Patient-Centric Formulations

Robert O. Williams III, PhD, is the division head and professor of molecular pharmaceutics and drug delivery at The University of Texas at Austin, College of Pharmacy; the Johnson & Johnson centennial chair in pharmacy at the University of Texas at Austin, College of Pharmacy; editor-in-chief of the AAPS PharmSciTech scientific journal; and the technology inventor/special advisor for TFF Pharmaceuticals.

How dry powder techniques can overcome limitations in biologics development and delivery to broaden routes of administration and global accessibility.

Improved Formulations to Enable Stable Delivery of Biologics

Greg Paddon-Jones, PhD, is director of Product Development at Antares Health Products.

The author discusses some new applications of TPGS in the pharmaceutical field that should see this versatile excipient retain its place in the drug formulators toolbox.

Emerging Applications of Vitamin E TPGS in Drug Delivery

Meg Rivers is the former senior editor for 

One company reaches beyond traditionally-conceived male contraceptives with Vasalgel, a reversible hydrogel injectable. 

The Next Generation of Male Contraceptives

Can Araman is the principal scientist, biomolecule formulation, for MilliporeSigma, the life science business of Merck KGaA, Darmstadt Germany.

Moritz Beck-Broichsitter is the associate director, formulation service, for MilliporeSigma, the life science business of Merck KGaA, Darmstadt Germany.

Nelli Erwin is the head of protein stability for MilliporeSigma, the life science business of Merck KGaA, Darmstadt Germany.

Supriyadi Hafiz is the senior scientist formulation for MilliporeSigma, the life science business of Merck KGaA, Darmstadt Germany.

Adela Kasselkus is the technical communication manager for MilliporeSigma, the life science business of Merck KGaA, Darmstadt Germany.

Thomas Kipping is the head of drug carriers for MilliporeSigma, the life science business of Merck KGaA, Darmstadt Germany.

David Luedeker is the principal scientist, solid formulation, for MilliporeSigma, the life science business of Merck KGaA, Darmstadt Germany.

Aditi Mehta is an associate director, mRNA process and delivery, for MilliporeSigma, the life science business of Merck KGaA, Darmstadt Germany.

Lena Mueller is the head of functional excipients for MilliporeSigma, the life science business of Merck KGaA, Darmstadt Germany.

Sara S. Nogueira is a scientist, RNA drug delivery, for MilliporeSigma, the life science business of Merck KGaA, Darmstadt Germany.

Tobias Rosenkranz is the head of biomolecule formulation for MilliporeSigma, the life science business of Merck KGaA, Darmstadt Germany.

Eleni Samaridou is the principal scientist formulation service for MilliporeSigma, the life science business of Merck KGaA, Darmstadt Germany.

Johanna Simon is the principal scientist formulation service for MilliporeSigma, the life science business of Merck KGaA, Darmstadt Germany.

Emerging new technologies and disruptive manufacturing concepts are providing new opportunities for pharmaceutical companies.

Seven Trends Shaping the Future of Pharmaceutical Formulation Development

Sponsors should explore key considerations ahead of choosing a new outsourcing partner.

CPHI Frankfurt: Selecting the Right Outsourcing Strategy and Partner

An expert from Aptamer Group reveals the potential of Optimers (a type of aptamer) in the realm of drug delivery, including its targeting capabilities, scalability, and key differences between Optimers and antibody-drug conjugates. 

Drug Solutions Podcast: Drug Delivery Systems: Optimer’s Therapeutic Targeting and Scaling Capabilities vs. ADCs

External expertise is beneficial in helping companies select the right tools at the right stages of development to ensure success.

Adopting Smart Development Strategies

Pramote Cholayudth previously was the managing director of the Professional Conference Center, Ltd. He currently is a validation consultant to Biolab Co., Ltd., in Thailand. He is the founder and manager of PM consult, cpramote2000@yahoo.com.

This article introduces a control chart technique using F statistic for continued process verification of oral solid dosage forms.

Formulation and Drug Delivery